Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
如果你已经准备好预约,选择一个button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
ldsports乐动RESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
癌症研究所应用科学(IACS)committed to apply our understanding of mechanisms driving tumor development and maintenance into the development of impactful small-molecule cancer drugs for our patients in need.
IACS is part of MD Anderson’sTherapeutics Discovery division, a unique group of clinicians, researchers and drug development experts working collaboratively to develop the next generation of targeted, immune- and cell-based therapies.
Embedded within the nation’s leading cancer center, the Therapeutics Discovery team leverages innovative academic science and clinical excellence to work with the benchatthe bedside. Using this approach, IACS works closely with the Moon Shots® and platforms to advance new targeted therapies to patients quickly, safely and effectively.
Cancer drug discovery remains an inefficient process, with challenges and bottlenecks that slow the development of new therapies. IACS and the Therapeutics Discovery division are working to overcome those obstacles through a unique, patient-driven approach only possible within MD Anderson.
IACS is built around a highly experienced team of professional drug discovery and development scientists, working seamlessly with world-class physicians and scientists and an unparalleled proximity to the clinic. Their mission is to design new small-molecule drugs that answer our patient’s most pressing needs.
This therapeutics engine has integrated translational medicine capabilities, including expertise in cancer biology, medicinal chemistry, pharmacology, structural biology, computational chemistry, animal modeling, computational and systems biology. IACS has successfully advanced multiple novel medicines from concept to clinical trials and has a robust portfolio of candidates being driven aggressively toward the clinic to improve patients’ lives.
一个新的靶向治疗阻止癌症新陈代谢has entered clinical trials at MD Anderson, marking the fourth novel medicine developed from concept to clinical trial by the Therapeutics Discovery division.
Learn moreMD Anderson, Artios Pharma and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program developed jointly by MD Anderson’s Therapeutics Discovery team and ShangPharma.
MD Anderson Therapeutics Discovery team identified and advances a drug that targets metabolic vulnerability
A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science and TRACTION platforms inhibits a vital metabolic process required for cancer cells’ growth and survival. IACS-10579 is the first small-molecule drug developed from concept to clinical trial by Therapeutics Discovery.
MD Anderson and Accelerator Life Science Partners have launched Magnolia Neuroscience Corporation to develop a new class of neuroprotective medicines based on discoveries made by researchers in the Institute for Applied Cancer Science and the Neurodegeneration Consortium.
